TherapeuticsMD full-year 2025 net loss narrows to $0.7 million on higher license revenue
TherapeuticsMD reported full-year 2025 results in a press release furnished on Form 8-K. The net loss from continuing operations narrowed to $0.7 million from $2.3 million in 2024, as license revenue rose 71.6% to $3.0 million and operating expenses fell 5.9% to $7.4 million. The company said it continues to explore strategic alternatives, including a possible acquisition, merger or sale of assets, but has set no timetable and gave no assurance of a transaction.
- Net loss from continuing operations was $(0.7) million, or $(0.06) per share, versus $(2.3) million, or $(0.20) per share, in 2024.
- License revenue, primarily from the Mayne License Agreement, was $3.0 million, up from $1.8 million in 2024.
- Total operating expenses were $7.4 million, down $0.5 million, mainly due to lower impairment charges.
- Cash and cash equivalents were $7.5 million as of December 31, 2025.